Exactly, I completely agree. The valuation of IMU and other biotech companies is huge compared to PEB. Lots of retailer holders (including myself) thought it was overvalued at 800m until I investigated some comparable ASX firms. Now I think it's cheap! I'm not expecting volumes to ramp up drastically this FY but the next two should see big growth in revenue. They receive $700USD for a test and it costs them $70USD to produce. - and their manufacturing is in the US already.
